ADVA introduces multi-layer cell site gateway to maximize 5G efficiency
5.9.2019 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro, a cell site gateway device specifically designed to meet the challenges of 5G. Ideal for deployment at radio base stations, the ADVA FSP 150-XG118Pro meets urgent demand for ultra-reliable low-latency communications (URLLC) in 5G mobile networks and supports a smooth transition from 1Gbit/s to 10Gbit/s services. The solution also features a temperature-hardened design and precise synchronization capabilities. What’s more, with its industry-leading demarcation technology and pluggable high-performance server, the FSP 150-XG118Pro enables virtual network functions (VNFs) to be hosted at the edge of the network and gives communication service providers (CSPs) and mobile wholesale operators a risk-free route to network functions virtualization (NFV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005062/en/
The ADVA FSP 150-XG118Pro is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure (Photo: Business Wire)
“Our FSP 150-XG118Pro brings high-capacity demarcation and edge aggregation to the radio base station without exceeding strict requirements for space, power and cost. It really is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure,” said Richard Strike, director, product line management, ADVA. “Our FSP 150-XG118Pro empowers mobile network operators (MNOs) to respond to soaring bandwidth needs with 10Gbit/s bandwidth at the radio base station. They can also cater for new URLLC applications that demand data to be processed right where it’s created. And, as the solution has been built with our Oscilloquartz team of network synchronization specialists, it delivers the accurate and stable timing that’s so crucial for 5G applications.”
The ADVA FSP 150-XG118Pro has been specifically engineered to support a seamless, cost-efficient transition from LTE mobile networks to 5G. With multi-layer demarcation and precise synchronization delivery, the cell site gateway device meets all current mobile network requirements, and its 10Gbit/s capacity enables MNOs to utilize the full 5G spectrum. Its open software-defined networking (SDN) control supports automated network slicing and its pluggable server allows it to be upgraded in-service for edge hosting of VNFs. The ADVA FSP 150-XG118Pro’s capacity and edge hosting capabilities also enable enterprises to unlock the potential of the industrial IoT (IIoT). This makes the solution ideal for a wide range of IIoT business cases that require ultra-low latency and massive machine connectivity.
“This new member of our hugely successful and widely deployed FSP 150 family opens the door to a world of new opportunities. It tears down the entry barriers and provides CSPs and businesses with a risk-free route to all the advantages of virtualization,” commented Ulrich Kohn, director, technical marketing, ADVA. “Featuring our award-winning, field-proven Ensemble Connector NFV hosting software, our FSP 150-XG118Pro enables enterprises to seize the full business potential of the IIoT. It supports big data analytics at the very edge of the network, saving significant bandwidth and improving performance. Now businesses can benefit from our vast experience with migrating centrally hosted network functions to the edge. Our customers can focus on revenue-generating services while we handle complex network integration and testing and ensure superb levels of performance.”
Watch this video for more information on the FSP 150-XG118Pro: http://adva.li/fsp-150-xg118pro-video.
Additional details can also be found in these slides: http://adva.li/fsp-150-xg118pro-slides.
A supporting solution brief can be downloaded here: http://adva.li/connecting-5g-new-radios.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005062/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom